Fig. 3.
En2 mRNA expression is elevated in high-grade serous tumours, with higher expression conveying poor prognosis. Malignant, borderline, benign and normal tumours were analysed, with mean En2 mRNA expression for each histological sub-type (a), or high grade serous tumours (HGSOCs) and non-malignant specimens (b), shown. Follow-up data was studied to determine if the patient had platinum-resistant (PFS < 6 months) or platinum-sensitive (PFS ≥ 6 months) disease. En2 mRNA expression is shown for all HGSOCs (c), and interval surgery HGSOCs versus platinum status (d)(p = 0.0232). Survival curves compare high versus low En2 expression for (e) overall survival in interval surgery HGSOCs (median OS = 28 vs. 42 months; p = 0.0329), (f) progression-free survival in all HGSOC specimens (median PFS = 9 vs. 18 months; p = 0,0036), and (g) progression-free survival in interval surgery HGSOCs (median PFS = 8 vs. 27 months; p = 0.0004). `En2 mRNA expression is shown relative to β-actin (× 100,000), using the ∆CT comparative method (2-∆Ct). Error bars represent the SE; (* = p < 0.05; ** = p < 0.01; *** = p < 0.001; **** = p < 0.0001)